1. Αρχική σελίδα
  2. Αναζήτηση

Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen

Το τεκμήριο παρέχεται από τον φορέα :
National Technical University of Athens   

Αποθετήριο :
Digital Library of National Technical University of Athens | Dspace@NTUA   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen (EN)
Georgala, S (EN)
Rook, AH (EN)
Schuster, SJ (EN)
Junkins-Hopkins, JM (EN)
Frankel, MC (EN)
Wasik, MA (EN)
Shapiro, M (EN)
Vittorio, CC (EN)
Itakura, H (EN)
journalArticle (EN)
2014-03-01T01:53:06Z
2003 (EN)
Although its cell of origin is still controversial, the blastic NK-cell leukemia/lymphoma clearly represents a distinct type of hematopoietic neoplasm that is particularly clinically aggressive when it occurs in elderly patients as a disseminated, multi-organ disease. Consistently effective treatments have not been developed for this malignancy. The present report describes two elderly patients with widespread blastic NK-cell leukemia/lymphoma involving the skin, bone marrow, peripheral blood, lymph nodes, and viscera. In both cases the malignant cells were CD56+, CD2+, and terminal deoxynucleotidyl transferase (TdT) positive with no detectable T-cell receptor (TCR) gamma chain gene rearrangement. The cells also exhibited a low CD45 expression and strong CD99 (mic-2) expression, as seen in immature lymphoid malignancies. The above findings support the precursor NK-cell, rather than mature NK- or non-NK-cell, origin of the malignant cells. It is noteworthy that the two patients achieved complete responses to treatment with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with high-dose methotrexate/cytarabine, a regimen currently utilized in acute lymphoblastic leukemia and high-grade lymphoma. The complete remission (CR) was sustained for 24 months in one patient who received four cycles (eight courses) of the treatment. It lasted 9 months in the second patient, who received only two cycles (four courses). If similar results are obtained with future patients, a randomized study comparing the hyper-CVAD regimen to other therapeutic strategies may be warranted. (C) 2003 Wiley-Liss, Inc. (EN)
Hematology (EN)
ACUTE-LEUKEMIA (EN)
blastic NK-cell lymphoma/leukemia (EN)
NASAL (EN)
LYMPHOBLASTIC LYMPHOMA (EN)
PRECURSOR (EN)
CD56(+) LYMPHOMA (EN)
CD4(+) (EN)
LOWER RESPIRATORY-TRACT (EN)
MALIGNANCIES (EN)
ASSOCIATION (EN)
hyper-CVAD (EN)
EPSTEIN-BARR-VIRUS (EN)
AMERICAN JOURNAL OF HEMATOLOGY (EN)
Αγγλική γλώσσα
WILEY-LISS (EN)
National Technical University of Athens
Digital Library of National Technical University of Athens | Dspace@NTUA
Κεντρική Βιβλιοθήκη Ε.Μ.Π.
Ιδρυματικό Αποθετήριο
Δημοσιεύσεις μελών Δ.Ε.Π. σε περιοδικά



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.